Recent Publications

Denna sida på svenska

If you do not have access to the full publication, please e-mail a request and we will send you a copy.

 

2016

Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.
Chiotis K, Saint-Aubert L, Savitcheva I, Jelic V, Andersen P, Jonasson M, et al
Eur. J. Nucl. Med. Mol. Imaging 2016 Aug;43(9):1686-99

Defeating Alzheimer's disease and other dementias: a priority for European science and society.
Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, et al
Lancet Neurol 2016 Apr;15(5):455-532

Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.
Rodriguez-Vieitez E, Carter S, Chiotis K, Saint-Aubert L, Leuzy A, Schöll M, et al
J. Nucl. Med. 2016 Jul;57(7):1071-7

Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
Rodriguez-Vieitez E, Saint-Aubert L, Carter S, Almkvist O, Farid K, Schöll M, et al
Brain 2016 Mar;139(Pt 3):922-36

Tracer Kinetic Analysis of (S)-18F-THK5117 as a PET Tracer for Assessing Tau Pathology.
Jonasson M, Wall A, Chiotis K, Saint-Aubert L, Wilking H, Sprycha M, et al
J. Nucl. Med. 2016 Apr;57(4):574-81

Amyloid-β peptides act as allosteric modulators of cholinergic signalling through formation of soluble BAβACs.
Kumar R, Nordberg A, Darreh-Shori T
Brain 2016 Jan;139(Pt 1):174-92

Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study.
Zwan M, Rinne J, Hasselbalch S, Nordberg A, Lleó A, Herukka S, et al
Neurology 2016 Jan;86(1):50-8

Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.
Heurling K, Leuzy A, Zimmer E, Lubberink M, Nordberg A
Eur. J. Nucl. Med. Mol. Imaging 2016 Feb;43(2):362-73

 

2015

Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment.
Nordberg A, Kadir A, Andreasen N, Almkvist O, Wall A, Långström B, et al
J. Alzheimers Dis. 2015 ;47(3):691-704

Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition.
Farid K, Carter S, Rodriguez-Vieitez E, Almkvist O, Andersen P, Wall A, et al
J. Alzheimers Dis. 2015 ;47(3):661-7

Investigation of the Binding Profiles of AZD2184 and Thioflavin T with Amyloid-β(1-42) Fibril by Molecular Docking and Molecular Dynamics Methods.
Kuang G, Murugan N, Tu Y, Nordberg A, Ågren H
J Phys Chem B 2015 Sep;119(35):11560-7

Neural Stem Cell Transplant-Induced Effect on Neurogenesis and Cognition in Alzheimer Tg2576 Mice Is Inhibited by Concomitant Treatment with Amyloid-Lowering or Cholinergic α7 Nicotinic Receptor Drugs.
Lilja A, Malmsten L, Röjdner J, Voytenko L, Verkhratsky A, Ögren S, et al
Neural Plast. 2015 ;2015():370432

Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue.
Lemoine L, Saint-Aubert L, Marutle A, Antoni G, Eriksson J, Ghetti B, et al
Acta Neuropathol Commun 2015 ;3():40

Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.
Chiotis K, Carter S, Farid K, Savitcheva I, Nordberg A,
Eur. J. Nucl. Med. Mol. Imaging 2015 Sep;42(10):1492-506

Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.
Ossenkoppele R, Jansen W, Rabinovici G, Knol D, van der Flier W, van Berckel B, et al
JAMA 2015 May;313(19):1939-49

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
Jansen W, Ossenkoppele R, Knol D, Tijms B, Scheltens P, Verhey F, et al
JAMA 2015 May;313(19):1924-38

Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study.
Rodriguez-Vieitez E, Ni R, Gulyás B, Tóth M, Häggkvist J, Halldin C, et al
Eur. J. Nucl. Med. Mol. Imaging 2015 Jun;42(7):1119-32

First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study.
Andreasen N, Simeoni M, Ostlund H, Lisjo P, Fladby T, Loercher A, et al
PLoS ONE 2015 ;10(3):e0098153

Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease.
Karami A, Eyjolfsdottir H, Vijayaraghavan S, Lind G, Almqvist P, Kadir A, et al
Alzheimers Dement 2015 Nov;11(11):1316-28

Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
Leuzy A, Carter S, Chiotis K, Almkvist O, Wall A, Nordberg A
J. Alzheimers Dis. 2015 ;45(4):1077-88

Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics.
Prestia A, Caroli A, Wade S, van der Flier W, Ossenkoppele R, Van Berckel B, et al
Alzheimers Dement 2015 Oct;11(10):1191-201

Dementia in 2014. Towards early diagnosis in Alzheimer disease.
Nordberg A
Nat Rev Neurol 2015 Feb;11(2):69-70

Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression.
Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier W, Ossenkoppele R, et al
Neurology 2015 Feb;84(5):508-15

Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics.
Prestia A, Caroli A, Wade S, van der Flier W, Ossenkoppele R, Van Berckel B, et al
Alzheimers Dement 2015 Oct;11(10):1191-201

Dementia in 2014. Towards early diagnosis in Alzheimer disease.
Nordberg A
Nat Rev Neurol 2015 Feb;11(2):69-70

Degree of abnormality is associated with rate of change in measures of beta-amyloid, glucose metabolism and cognition in an autopsy-verified Alzheimer's disease case.
Almkvist O, Kadir A, Nordberg A
Neurocase 2015 ;21(6):738-47

Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimer's disease patients and control subjects.
Varrone A, Oikonen V, Forsberg A, Joutsa J, Takano A, Solin O, et al
Eur. J. Nucl. Med. Mol. Imaging 2015 Mar;42(3):438-46

The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey.
Bocchetta M, Galluzzi S, Kehoe P, Aguera E, Bernabei R, Bullock R, et al
Alzheimers Dement 2015 Feb;11(2):195-206.e1

 

2014

Promising two-photon probes for in vivo detection of β amyloid deposits.
Murugan N, Zaleśny R, Kongsted J, Nordberg A, Ågren H
Chem. Commun. (Camb.) 2014 Oct;50(79):11694-7

Glial Asthenia and Functional Paralysis: A New Perspective on Neurodegeneration and Alzheimer's Disease.
Verkhratsky A, Marutle A, Rodríguez-Arellano J, Nordberg A
Neuroscientist 2014 Aug;():

Astrocytosis measured by ¹¹C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients.
Choo I, Carter S, Schöll M, Nordberg A
Eur. J. Nucl. Med. Mol. Imaging 2014 Nov;41(11):2120-6

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.
Dubois B, Feldman H, Jacova C, Hampel H, Molinuevo J, Blennow K, et al
Lancet Neurol 2014 Jun;13(6):614-29

Molecular imaging in sporadic Alzheimer's disease populations and those genetically at risk.
Nordberg A
Neurodegener Dis 2014 ;13(2-3):160-2

Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
Darreh-Shori T, Hosseini S, Nordberg A
J. Alzheimers Dis. 2014 ;39(2):423-40

 

2013

Imaging markers for Alzheimer disease: which vs how.
Frisoni G, Bocchetta M, Chételat G, Rabinovici G, de Leon M, Kaye J, et al
Neurology 2013 Jul;81(5):487-500

³H-deprenyl and ³H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain.
Marutle A, Gillberg P, Bergfors A, Yu W, Ni R, Nennesmo I, et al
J Neuroinflammation 2013 ;10():90

Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease.
Darreh-Shori T, Vijayaraghavan S, Aeinehband S, Piehl F, Lindblom R, Nilsson B, et al
Neurobiol. Aging 2013 Nov;34(11):2465-81

Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue.
Ni R, Gillberg P, Bergfors A, Marutle A, Nordberg A
Brain 2013 Jul;136(Pt 7):2217-27

Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid-β levels.
Lilja A, Röjdner J, Mustafiz T, Thomé C, Storelli E, Gonzalez D, et al
PLoS ONE 2013 ;8(3):e58752

Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease.
Prestia A, Caroli A, van der Flier W, Ossenkoppele R, Van Berckel B, Barkhof F, et al
Neurology 2013 Mar;80(11):1048-56

Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease.
Lilja A, Luo Y, Yu Q, Röjdner J, Li Y, Marini A, et al
PLoS ONE 2013 ;8(1):e54887

Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients.
Choo I, Ni R, Schöll M, Wall A, Almkvist O, Nordberg A
J. Alzheimers Dis. 2013 ;33(4):929-39

Modulation of α7 nicotinic acetylcholine receptor and fibrillar amyloid-β interactions in Alzheimer's disease brain.
Ni R, Marutle A, Nordberg A
J. Alzheimers Dis. 2013 ;33(3):841-51

A European multicentre PET study of fibrillar amyloid in Alzheimer's disease.
Nordberg A, Carter S, Rinne J, Drzezga A, Brooks D, Vandenberghe R, et al
Eur. J. Nucl. Med. Mol. Imaging 2013 Jan;40(1):104-14

 

1998- 2012

List of publications